IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 1-25 out of 1252.

1 | 2 | 3 | 4 | 5 > >>

Public Release: 8-Dec-2016
JAMA Oncology
Study shows new treatment strategy in head & neck cancer not better than current standard
Results of the largest Canadian clinical trial to date comparing standard treatment for locally advanced squamous cell head and neck cancer with an experimental treatment did not show the new treatment is superior.
Amgen Inc., Canadian Cancer Society Research Institute, The Princess Margaret Cancer Foundation

Contact: Jane Finlayson
University Health Network

Public Release: 8-Dec-2016
JAMA Oncology
Tumor found in a 255-million-year-old mammalian ancestor
A tumor in a 255-million-year-old mammalian ancestor called a gorgonopsian is detailed in a new research letter published online by JAMA Oncology.

Contact: James Urton
The JAMA Network Journals

Public Release: 8-Dec-2016
JAMA Oncology
Blood-borne HPV antibodies indicate head, neck cancer prognosis
A new study in JAMA Oncology finds that the presence of particular antibodies of human papillomavirus in blood serum are reliable indicators of five-year head and neck cancer survival.
NIH/National Cancer Institute, NIH/National Institutes of Environmental Health Sciences, Minnesota Masonic Charities

Contact: David Orenstein
Brown University

Public Release: 8-Dec-2016
Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
Scientists have focused on certain p53 mutations that generate mutant proteins that promote cancer growth and metastasis. The variants studied are truncated -- they lack half of the domains, or units, of the full-length p53 protein, which enable full-length p53 to enter the cell nucleus and bind DNA, essential in its normal tumor-suppressor function. The truncated mutants act by perturbing mitochondrial function, the team proposes.
NIH/National Cancer Institute, Swim Across America

Contact: Peter Tarr
Cold Spring Harbor Laboratory

Public Release: 8-Dec-2016
San Antonio Breast Cancer Symposium
Radiation therapy may increase complications in breast cancer patients receiving implants
Radiotherapy increased complications and impaired patient-reported satisfaction with reconstructed breasts in breast cancer patients who received implant reconstruction but not in those who received autologous reconstruction, according to data from a large, prospective, multicenter cohort study presented at the 2016 San Antonio Breast Cancer Symposium, held Dec. 6-10.
NIH/National Cancer Institute

Contact: Lauren Riley
American Association for Cancer Research

Public Release: 8-Dec-2016
San Antonio Breast Cancer Symposium
More complications, less satisfaction in breast cancer patients who get radiation, implants
A new study finds that breast cancer patients who have implant reconstruction following radiation therapy had more complications from the surgery and were less satisfied with the result than women who had implants but no radiation.
NIH/National Cancer Institute

Contact: Nicole Fawcett
University of Michigan Health System

Public Release: 8-Dec-2016
Journal of Molecular Diagnostics
DNA methylation biomarker for prostate cancer shows promise for accurately determining patient risk
Report in The Journal of Molecular Diagnostics describes a biomarker, PITX2 DNA methylation, which is capable of distinguishing cancerous tissue from non-cancerous tissue and predicting the risk of cancer recurrence using only small amounts of tissue obtained from core needle biopsies.
University Hospital Bonn

Contact: Eileen Leahy
Elsevier Health Sciences

Public Release: 8-Dec-2016
Genome Biology
Tracking breast cancer cell genetics reveals longer potential treatment window
Breast cancer cells break away and spread to other parts of the body relatively late on in breast tumor development, an international team of scientists has shown. The research, jointly led by Dr. Peter Van Loo at the Francis Crick Institute, could help refine cancer therapy and is published in the journal Genome Biology.
K G Jebsen Centre for Breast Cancer Research in Norway, Research Council of Norway, Norwegian Cancer Society, South-Eastern Norway Regional Health Authority, Research Foundation - Flanders, Foundation against Cancer in Belgium, KU Leuven

Contact: Francis Crick Institute Press Office
The Francis Crick Institute

Public Release: 8-Dec-2016
San Antonio Breast Cancer Symposium
UH Seidman cancer center expert presents triple-negative breast cancer immunotherapy trial
A researcher from UH Seidman Cancer Center will discuss his upcoming immunotherapy clinical trial for triple-negative breast cancer at 2016 San Antonio Breast Cancer Symposium. Joseph Baar, MD, PhD, Director of Breast Cancer Research at UH Seidman Cancer Center, will share details about a phase II clinical trial testing the effectiveness of combining carboplatin and nab-paclitaxel with an immunotherapeutic agent called pembrolizumab in patients with metastatic triple-negative breast cancer.

Contact: Alicia Reale
University Hospitals Cleveland Medical Center

Public Release: 8-Dec-2016
Molecular Cell
Scientists reveal 'safety catch' within all dividing cells
Researchers have made a major discovery about how cells control when to divide -- representing a step forward in scientists' understanding of one of the most fundamental processes of life.
Cancer Research UK, Wellcome, Science Foundation Ireland, European Union

Contact: Sophia McCully
Institute of Cancer Research

Public Release: 8-Dec-2016
San Antonio Breast Cancer Symposium
Researchers identify biomarkers of response to treatment in invasive breast cancer
Researchers report at the San Antonio Breast Cancer Symposium that they have identified biomarkers they believe can be used as part of a larger model to predict how patients with HER2-positive operative breast cancer will respond to the targeted treatment trastuzumab, commercially known as Herceptin, and chemotherapy.

Contact: Laura Oleniacz
UNC Lineberger Comprehensive Cancer Center

Public Release: 8-Dec-2016
New England Journal of Medicine
Treating cancer, mental health neglect in rural America
OHSU Knight Cancer Institute oncologist publishes New England Journal of Medicine 'Perspective' on her experience treating a patient in rural Oregon with breast cancer, mental illness.

Contact: Amanda Gibbs
Oregon Health & Science University

Public Release: 8-Dec-2016
European Journal of Immunology
Localized immunotherapy new possibility to treat bladder cancer
Antibody-based immunotherapy is a new promising method to treat cancer. Unfortunately, today's treatments can result in adverse side effects. New findings from Uppsala University show an alternative way to administer the therapy, which has the same effect on the tumor but less impact other parts of the body.

Contact: Sara Mangsbo
Uppsala University

Public Release: 8-Dec-2016
Prostate cancer patients more likely to die of other diseases, say 15-year PLCO results
15-year PLCO results published this month in Cancer: 'Most men diagnosed with prostate cancer will not die from their disease... now we need to focus on discovering the men that will,' says E. David Crawford, M.D., investigator at the University of Colorado Cancer Center.

Contact: Garth Sundem
University of Colorado Anschutz Medical Campus

Public Release: 8-Dec-2016
Royal Society Interface
Rice scientists' study of human migration could help understand cancer metastasis
A new Rice University study finds that migration for the first humans in America was easier moving east-west as opposed to north-south, largely because the knowledge needed to live in the same climate zones was easily transferable. Researchers said the findings could also shed light on the behavior of metastatic cancers.

Contact: David Ruth
Rice University

Public Release: 7-Dec-2016
Chemical Communications
Scientists develop exciting new option for targeted cancer therapy
Scientists at Trinity College Dublin have identified a new option for more targeted cancer therapy. Their method should allow greater doses of cancer drugs to be administered with fewer side-effects, because the drugs are inactive in the body until being sparked into life when coming into contact with cancer cells.
Science Foundation Ireland

Contact: Thomas Deane
Trinity College Dublin

Public Release: 7-Dec-2016
BMC Public Health
Public urged to be more body vigilant in fight against cancer, new study finds
New research published in BMC Public Health has found that increased body vigilance may contribute to early cancer diagnosis. In the first study of its kind, researchers from the University of Surrey who received funding from Cancer Research UK, found that people who are more body vigilant were more likely to seek professional medical help.

Contact: Natasha Meredith
University of Surrey

Public Release: 7-Dec-2016
Genome Research
Atlas of the RNA universe takes shape
In the last few years, small snippets of RNA, which may have played a key role in the planet's earliest flickering of life, have been uncovered and examined in great detail. Their discovery, first in the tiny soil-dwelling nematode worm C. elegans and shortly thereafter, across the web of life, marks a revolution in biology, with broad implications in the fight against nearly every known disease.

Contact: Richard Harth
Arizona State University

Public Release: 7-Dec-2016
ESMO Asia 2016 Congress
Supportive care for cancer patients remains inadequate
Pain relief and other forms of supportive care for cancer patients are insufficient, researchers report at the ESMO ASIA 2016 Congress in Singapore. They also highlight that side-effects to chemotherapy must be treated efficiently and that doctors should ensure end-of-life treatment meets patients' expectations.

Contact: ESMO Press Office
European Society for Medical Oncology

Public Release: 7-Dec-2016
Scientific Reports
Safety in darkness
With a little help from chickens and video cameras, scientists have captured live the moment when skin gets darker. In a study appearing in Scientific Reports, a Japanese team has filmed and demystified the process by which melanin -- molecules that give skin its color -- are carried to the epidermis.
AMED Core Research for Evolutional Science and Technology, Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science

Contact: David Kornhauser
Kyoto University

Public Release: 7-Dec-2016
Two genetic mutations discovered in subset of acute myeloid leukemia
Two genetic mutations known to play a role in many solid cancers might also help explain why a subset of acute myeloid leukemia (AML) patients develop the disease.
NIH/National Cancer Institute, Leukemia Clinical Research Foundation, Warren D. Brown Foundation, Pelotonia Fellowship Program

Contact: Amanda Harper
Ohio State University Wexner Medical Center

Public Release: 7-Dec-2016
Researchers reveal 3-D structure of cell's inflammation sensor and its inhibitors
Researchers at the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego have now determined the 3-D structure of CCR2 simultaneously bound to two inhibitors. Understanding how these molecules fit together may better enable pharmaceutical companies to develop anti-inflammatory drugs that bind and inhibit CCR2 in a similar manner. The study is published Dec. 7 by Nature.
National Institutes of Health

Contact: Heather Buschman
University of California - San Diego

Public Release: 7-Dec-2016
American Journal of Physiology
Enzyme that digests vitamin A also may regulate testosterone levels
Bco1, an enzyme that metabolizes beta carotene, may play a vital role in testosterone metabolism as well, according to a new study led by researchers at the University of Illinois.
National Institutes of Health

Contact: Sharita Forrest
University of Illinois at Urbana-Champaign

Public Release: 7-Dec-2016
Tumor cells are dependent on fat to start metastasis
A study headed by Salvador Aznar Benitah, ICREA researcher at the Institute for Research in Biomedicine (IRB Barcelona), and published today in Nature identifies metastasis-initiating cells through a specific marker, namely the protein CD36. This protein, which is found in the membranes of tumor cells, is responsible for taking up fatty acids. CD36 activity and dependence on lipid (fat) metabolism distinguish metastasis-initiating cells from other tumor cells.
Fundació La Marató de TV3, World Wide Cancer Research of the UK, Fundación Botín and Banco Santander, European Research Council

Contact: Sònia Armengou
Institute for Research in Biomedicine (IRB Barcelona)

Public Release: 7-Dec-2016
IASLC 2016 World Conference on Lung Cancer
Summary of research presented at the IASLC 17th World Conference on Lung Cancer
Today's press briefing at the IASLC 17th World Conference on Lung Cancer (WCLC) focused on clinical trials that advance the progress made in lung cancer treatment through immunotherapy and better diagnostics. Abstracts and full versions of news releases for each topic covered are available through links in this summary, or through IASLC media representative Chris Martin.

Contact: Chris Martin
International Association for the Study of Lung Cancer

Showing releases 1-25 out of 1252.

1 | 2 | 3 | 4 | 5 > >>

  Search News Releases